Nocerino A, Valencic E, Loganes C, Pelos G, Tommasini A. Low-dose sirolimus in two cousins with autoimmune lymphoproliferative syndrome-associated infection. Pediatr Int 2018;60(3):315-317.

Marcuzzi A, Loganes C, Valencic E, Piscianz E, Monasta L, Bilel S, Bortul R, Celeghini C, Zweyer M, Tommasini A. Neuronal Dysfunction Associated with Cholesterol Deregulation. Int J Mol Sci 2018;19(5)

Valencic E, Grasso AGiacomo, Conversano E, Lucafò M, Piscianz E, Gregori M, Conti F, Cancrini C, Tommasini A. Theophylline as a precision therapy in a young girl with PIK3R1 immunodeficiency. J Allergy Clin Immunol Pract 2018;6(6):2165-2167.

Loganes C, Lega S, Bramuzzo M, Brumatti LVecchi, Piscianz E, Valencic E, Tommasini A, Marcuzzi A. Curcumin Anti-Apoptotic Action in a Model of Intestinal Epithelial Inflammatory Damage. Nutrients 2017;9(6)

Cason C, Campisciano G, Zanotta N, Valencic E, Delbue S, Bella R, Comar M. SV40 Infection of Mesenchymal Stromal Cells From Wharton's Jelly Drives the Production of Inflammatory and Tumoral Mediators. J Cell Physiol 2017;232(11):3060-3066.

Piscianz E, Candilera V, Valencic E, Loganes C, Paron G, De Iudicibus S, Decorti G, Tommasini A. Action of methotrexate and tofacitinib on directly stimulated and bystander-activated lymphocytes. Mol Med Rep 2016;14(1):574-82.

Abate MValentina, Stocco G, Devescovi R, Carrozzi M, Pierobon C, Valencic E, Lucafò M, Di Silvestre A, d'Adamo P, Tommasini A, Decorti G, Ventura A. Carbamazepine-induced thrombocytopenic purpura in a child: Insights from a genomic analysis. Blood Cells Mol Dis 2016;59:97-9.

Tricarico PMaura, Girardelli M, Kleiner G, Knowles A, Valencic E, Crovella S, Marcuzzi A. Alendronate, a double-edged sword acting in the mevalonate pathway. Mol Med Rep 2015;12(3):4238-42.

Lougaris V, Faletra F, Lanzi G, Vozzi D, Marcuzzi A, Valencic E, Piscianz E, Bianco AM, Girardelli M, Baronio M, Loganes C, Fasth A, Salvini F, Trizzino A, Moratto D, Facchetti F, Giliani S, Plebani A, Tommasini A. Altered germinal center reaction and abnormal B cell peripheral maturation in PI3KR1-mutated patients presenting with HIGM-like phenotype. Clin Immunol 2015;159(1):33-6.

Taddio A, Tommasini A, Valencic E, Biagi E, Decorti G, De Iudicibus S, Cuzzoni E, Gaipa G, Badolato R, Prandini A, Biondi A, Ventura A. Failure of interferon-? pre-treated mesenchymal stem cell treatment in a patient with Crohn's disease. World J Gastroenterol 2015;21(14):4379-84.

Marcuzzi A, Piscianz E, Valencic E, Monasta L, Brumatti LVecchi, Tommasini A. To Extinguish the Fire from Outside the Cell or to Shutdown the Gas Valve Inside? Novel Trends in Anti-Inflammatory Therapies. Int J Mol Sci 2015;16(9):21277-93.

Frausin S, Viventi S, Falzacappa LVerga, Quattromani MJlenia, Leanza G, Tommasini A, Valencic E. Wharton's jelly derived mesenchymal stromal cells: Biological properties, induction of neuronal phenotype and current applications in neurodegeneration research. Acta Histochem 2015;117(4-5):329-38.

Tricarico PMaura, Kleiner G, Valencic E, Campisciano G, Girardelli M, Crovella S, Knowles A, Marcuzzi A. Block of the mevalonate pathway triggers oxidative and inflammatory molecular mechanisms modulated by exogenous isoprenoid compounds. Int J Mol Sci 2014;15(4):6843-56.

Piscianz E, Valencic E, Cuzzoni E, De Iudicibus S, De Lorenzo E, Decorti G, Tommasini A. Fate of lymphocytes after withdrawal of tofacitinib treatment. PLoS One 2014;9(1):e85463.

Pastore S, Barbieri F, Di Leo G, Valencic E, Tommasini A, Ventura A. Hemophagocytic lymphohistiocytosis in total parenteral nutrition dependent children: description of 5 cases and practical tips for management. J Pediatr Hematol Oncol 2014;36(7):e440-2.

Comar M, Delbue S, Zanotta N, Valencic E, Piscianz E, Del Savio R, Tesser A, Tommasini A, Ferrante P. In vivo detection of polyomaviruses JCV and SV40 in mesenchymal stem cells from human umbilical cords. Pediatr Blood Cancer 2014;61(8):1347-9.

Valencic E, Loganes C, Cesana S, Piscianz E, Gaipa G, Biagi E, Tommasini A. Inhibition of mesenchymal stromal cells by pre-activated lymphocytes and their culture media. Stem Cell Res Ther 2014;5(1):3.

Farchi S, Forastiere F, Brumatti LVecchi, Alviti S, Arnofi A, Bernardini T, Bin M, Brescianini S, Colelli V, Cotichini R, Culasso M, De Bartolo P, Felice L, Fiano V, Fioritto A, Frizzi A, Gagliardi L, Giorgi G, Grasso C, La Rosa F, Loganes C, Lorusso P, Martini V, Merletti F, Medda E, Montelatici V, Mugelli I, Narduzzi S, Nisticò L, Penna L, Piscianz E, Piscicelli C, Poggesi G, Porta D, Ranieli A, Rapisardi G, Rasulo A, Richiardi L, Rusconi F, Serino L, Stazi MAntonietta, Toccaceli V, Todros T, Tognin V, Trevisan M, Valencic E, Volpi P, Ziroli V, Ronfani L, Di Lallo D. Piccolipiù, a multicenter birth cohort in Italy: protocol of the study. BMC Pediatr 2014;14:36.

Taddio A, Biondi A, Piscianz E, Valencic E, Biagi E, Badolato R. From bone marrow transplantation to cellular therapies: possible therapeutic strategies in managing autoimmune disorders. Curr Pharm Des 2012;18(35):5776-81.

Tommasini A, Valencic E, Piscianz E, Rabusin M. Immunomodulatory drugs in autoimmune lymphoproliferative syndrome (ALPS). Pediatr Blood Cancer 2012;58(2):310; author reply 311.

Piscianz E, Cuzzoni E, De Iudicibus S, Valencic E, Decorti G, Tommasini A. Differential action of 3-hydroxyanthranilic acid on viability and activation of stimulated lymphocytes. Int Immunopharmacol 2011;11(12):2242-5.